莱美药业控股子公司获得药物临床试验批准通知书

Core Viewpoint - Laimei Pharmaceutical's subsidiary, Sichuan Yingrui Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," in combination with standard radiotherapy for solid tumor patients [1] Group 1 - The approved clinical trial aims to further validate the safety and potential efficacy of the "Nano Carbon Iron + Radiotherapy" combination therapy [1] - The trials will be initiated at multiple clinical centers, focusing on solid tumors that are difficult to treat locally [1] - The objective is to explore the clinical value of the combination therapy while ensuring safety [1]